Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Antibodies to infliximab and risk of infusion reactions in patients with IBD

The most recent issue of the Inflammatory Bowel Diseases investigates antibodies to infliximab and risk of infusion reactions in patients with IBD.

News image

Antibodies to infliximab have been associated with a risk of infusion reactions in some studies of patients with inflammatory bowel disease.

However, many factors, such as immunomodulators and dosing schedule, may influence this association.

Dr O’Meara and colleagues provided a pooled estimate of the risk of infusion reactions according to patients’ antibodies to infliximab status and analyze the relationship of immunomodulators to this risk.

Public databases were searched for eligible studies.

Quality assessment was undertaken for all studies using Grading of Recommendations Assessment, Development and Evaluation criteria.

Raw data from studies meeting inclusion criteria were pooled for meta-analysis of effect estimates.

7 of the 8 studies had a high risk of bias in at least 1 quality domain
Inflammatory Bowel Diseases

Sensitivity analysis was performed for all outcomes. Funnel plot was performed to assess for publication bias.

The team identified 8 studies met the inclusion criteria, with a pooled total of 1351 subjects.

The researchers found 7 of the 8 studies had a high risk of bias in at least 1 quality domain.

The cumulative data indicated that there was a higher risk ratio (RR) of any acute infusion reaction, and severe infusion reactions in patients with antibodies to infliximab when compared with patients without antibodies to infliximab.

The team noted that RR of delayed hypersensitivity reactions was not significantly different between antibodies to infliximab positive and negative patients.

The researchers reported that patients prescribed immunomodulators during maintenance infliximab therapy had a reduction in their risk for antibodies to infliximab development, and infusion reactions.

Dr O’Meara's team concludes, "The presence of antibodies to infliximab is associated with a significantly higher risk of acute infusion reactions, but not delayed hypersensitivity reactions, in patients with inflammatory bowel disease."

"Concomitant immunomodulators reduce this risk."

Inflamm Bowel Dis 2014: 20(1): 1-6
21 January 2014

Go to top of page Email this page Email this page to a colleague

 22 October 2014

Advanced search
 22 October 2014 
Liver fibrosis prognostic biomarkers in type-2 diabetes
 22 October 2014 
H pylori eradication with multiple drug resistance
 22 October 2014 
Early-TIPSS placement prevents rebleeding
 21 October 2014 
Scoring systems for critically ill cirrhotic patients
 21 October 2014 
Aspirin and NAFLD
 21 October 2014 
Alcohol and Barrett's
 20 October 2014 
Drug resistant H pylori eradication
 20 October 2014 
Adalimumab in secondary loss of response in Crohn's
 20 October 2014 
Omega-3 and colorectal cancer
 17 October 2014 
Colorectal testing utilization
 17 October 2014 
Fecal microbiota composition in postinfectious IBS
 17 October 2014 
Tumor necrosis factor-alpha inhibitors and pregnancy in IBD
 16 October 2014 
Risk of Barrett's esophagus
 16 October 2014 
Aspirin tablets and colorectal tumours
 16 October 2014 
Economic impact of IBS
 15 October 2014 
Achieving competency at colonoscopy
 15 October 2014 
Preparation for surgery in Crohn's
 15 October 2014 
Bowel preparations
 14 October 2014 
Colorectal testing utilization in commercially insured US adults
 14 October 2014 
Sustained response to infliximab
 14 October 2014 
IBD management during pregnancy
 13 October 2014 
Predicting PPI response in GERD-related cough
 13 October 2014 
Probiotics in IBS
 13 October 2014 
Use of azathioprine in IBD
 10 October 2014 
NAFLD in the Veterans Administration population
 10 October 2014 
Liver injury from herbals and dietary supplements
 10 October 2014 
Predictors for cecal insertion time
 09 October 2014 
Methotrexate-related liver disease and metabolic syndrome
 09 October 2014 
Biomarkers of acetaminophen overdose patients
 09 October 2014 
Postoperative adhesions in digestive surgery
 08 October 2014 
Feeding intervention in celiac disease infants
 08 October 2014 
Gluten introduction in high risk children
 08 October 2014 
Vitamin D and HCC
 07 October 2014 
Infliximab in pediatric perianal Crohn's
 07 October 2014 
Omega-3 and NAFLD
 07 October 2014 
Endoscopic submucosal dissection in the colorectum 
 06 October 2014 
Clinical indications for computed tomographic colonography
 06 October 2014 
Certolizumab pegol in the treatment of Crohn's
 06 October 2014 
Costs of telaprevir therapy for Hep C
 03 October 2014 
Depression and liver transplantation
 03 October 2014 
Orange juice intake during bowel preparation
 03 October 2014 
HCV and diabetes
 02 October 2014 
Predictive model of Hep C disease progression
 02 October 2014 
IPAA with or without preoperative radiation
 02 October 2014 
Person-to-person transmission of norovirus
 01 October 2014 
Prevention of postop Crohn's
 01 October 2014 
Cecal intubation time during colonoscopy
 01 October 2014 
Anti-TNFa therapies during pregnancy in IBD
 30 September 2014 
Autoimmune hepatitis
 30 September 2014 
Medication use in patients with chronic Hep C
 30 September 2014 
Gastric cancer according to H pylori infection status
 29 September 2014 
Drug exposure and microscopic colitis
 29 September 2014 
Peptic ulcer bleeding after PPI treatment
 29 September 2014 
Intestinal tuberculosis vs Crohn's disease
 26 September 2014 
5-aminosalicylates for the treatment of Crohn's
 26 September 2014 
Response to infliximab in paediatric perianal Crohn's
 26 September 2014 
Ondansetron for IBS with diarrhea
 25 September 2014 
Medical treatment and surgery rates in IBD
 25 September 2014 
Liver transplants for liver cancer
 25 September 2014 
Colorectal neoplasia among family members of patients with colorectal cancer

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2014 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us